The Sloan-Kettering Institute for Cancer Research, a division of Memorial Sloan-Kettering Cancer Center, last month filed suit against Amgen for allegedly underpaying royalties on the anti-infectives Neupogen and Neulasta by more than $72 million.
 
Sloan-Kettering, one of the top hospitals or non-profit research institutions in the US in terms of licensing revenues, has likely brought in at least $100 million in royalties from the blockbuster drugs since they were approved in 1991 and 2002, respectively.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.